Metraipolis › archive › dc_d18d579e34cf

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models — Europe PMC PMID:42092176

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42092176
DOI
10.1038/s41416-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-11-02T17:36:07.119Z
SHA-256 of the archived text
d8dd73092d86eb6291493b74cfed082f5b9cb1e4af240366915bd6b9ee66ea2c
Stable URL of this page
https://metraipolis.com/documento/dc_d18d579e34cf

How to cite

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models — Europe PMC PMID:42092176 — Europe PMC (en), https://europepmc.org/article/MED/42092176 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d18d579e34cf (Metraipolis archive dc_d18d579e34cf, sha256 d8dd73092d86eb6291493b74cfed082f5b9cb1e4af240366915bd6b9ee66ea2c)
BibTeX
@misc{dcd18d579e34cf,
  title = {JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models — Europe PMC PMID:42092176},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42092176},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d18d579e34cf; sha256 d8dd73092d86eb6291493b74cfed082f5b9cb1e4af240366915bd6b9ee66ea2c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42092176. Agents can read the archived copy with the MCP tool read_document.